Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,736 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Administration first Clear all

Conditions: Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon, Cancer, Gall Bladder, Myeloma Multiple, Glioblastoma Multiforme
Interventions: Cannabidiol, Bortezomib, Leucovorin, 5-FU, Oxaliplatin, Bevacizumab, Irinotecan, Gemcitabine, Temozolomide; Drug
Lead sponsor: Leaf Vertical Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: End Stage Renal Disease (ESRD), Vascular Access Complication
Interventions: Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC), Placebo, Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC); Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HIV-1 Infection
Interventions: ABC/DTG/3TC, B/F/TAF, ABC/DTG/3TC Placebo, B/F/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 631 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 78
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Sotagliflozin (SAR439954), Placebo, Metformin, Sulfonylurea; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 28
States / cities: Litchfield Park, Arizona • Peoria, Arizona • Greenbrae, California + 25 more

Conditions: Healthy Volunteer, Psoriasis
Interventions: ABBV-547, ABBV-547 Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 18
States / cities: Birmingham, Alabama • Bryant, Arkansas • Anaheim, California + 15 more

Conditions: Epigastric Pain Syndrome
Interventions: AutoSTEA device, Sham treatment; Device
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 2
States / cities: Cleveland, Ohio • Parma, Ohio

Conditions: Healthy Subjects
Interventions: AZD1979, Placebo to match; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Schizophrenia
Interventions: PF 03654746, Placebo; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 40 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Palsy Supranuclear, Supranuclear Palsy, Progressive
Interventions: Repetitive transcranial magnetic stimulation (rTMS); Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 40 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Chronic Hepatitis B
Interventions: Placebo (PLB), Adefovir Dipivoxil (ADV), Lamivudine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Opioid Abuse, Opioid Dependence
Interventions: MN-166 (50 mg) First, Placebo First; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Severe Sepsis With Septic Shock
Interventions: Interleukin-7, Placebo; Drug
Lead sponsor: Revimmune; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
Interventions: Carboplatin, Laboratory Biomarker Analysis, Metformin Hydrochloride, Paclitaxel, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 431
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 298 more

Conditions: Restless Leg Syndrome
Interventions: incobotulinumtoxinA, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Mucocutaneous Lymph Node Syndrome, Kawasaki Disease
Interventions: Etanercept, Placebo; Drug
Lead sponsor: Michael Portman; Other
Eligibility: 2 Months to 20 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 7
States / cities: New Hyde Park, New York • New York, New York • The Bronx, New York + 4 more

Conditions: Small Cell Lung Cancer (SCLC)
Interventions: Pembrolizumab, Normal saline solution, Carboplatin, Cisplatin, Etoposide; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 27
States / cities: Miami, Florida • Chicago, Illinois • Evanston, Illinois + 21 more

Conditions: Cardiovascular Disease, HIV, Atherosclerosis, Inflammation, Statins, HMG-CoA, HIV Infections
Interventions: atorvastatin, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Burns
Interventions: Recombinant Factor VIIa, Placebo; Drug
Lead sponsor: United States Army Institute of Surgical Research; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Disinhibition Syndrome
Interventions: AVP-786, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Schizophrenia
Interventions: AMG 579, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Glendale, California

Conditions: Smoking Cessation, Bipolar Disorder
Interventions: Varenicline, Placebo; Drug
Lead sponsor: K.N. Roy Chengappa; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: DuBois, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Chronic Pain, Post-traumatic Stress Disorder
Interventions: Brief Prolonged Exposure Protocol, Chronic Pain Management Treatment, Self-Care; Behavioral
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years to 70 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 4
States / cities: Arlington, Texas • Fort Sam Houston, Texas • Lackland Air Force Base, Texas + 1 more

Conditions: Autism Spectrum Disorders
Interventions: Double blind phase Placebo Nasal Spray, double Blind Oxytocin Nasal Spray, Open Label intranasal oxytocin; Drug
Lead sponsor: Linmarie Sikich; Other
Eligibility: 3 Years to 17 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 7
States / cities: Boston, Massachusetts • New York, New York • White Plains, New York + 3 more

Conditions: Graft-versus-host Disease (GVHD)
Interventions: Itacitinib, Placebo, Prednisone, Methylprednisolone; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 49
States / cities: La Jolla, California • Los Angeles, California • Stanford, California + 38 more

Search by objective public record fields.

A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections

TEA Synchronized With Natural Breathing for EPS

A First Time in Man Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1979 in Healthy Males

Add On Treatment for Cognitive Deficits in Schizophrenia

Transcranial Magnetic Stimulation in Progressive Supranuclear Palsy

Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B

Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers

A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients

Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer

Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.

A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

Statin Therapy to Improve Atherosclerosis in HIV Patients

Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn

Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition

First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia

Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder

Treatment of Post-Traumatic Stress Disorder (PTSD) and Chronic Pain After Traumatic Orthopedic Injury

Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors

GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease